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Abstract. There have been many discrepant observations on
the serum levels of cytokines in cancer patients and their
prognostic value. The purpose of this study was to determine
the plasma levels of pro- and anti-inflammatory cytokines
and their clinical significance in a large group of patients
with gastric carcinoma. The levels of tumour necrosis factor
alpha (TNF α), interleukin-12p40 (IL-12p40), IL-12p70,
IL-18, IL-10 and soluble TNF receptors I and II sTNF-Rs
were investigated in the plasma of 136 consecutive patients
with biopsy proven gastric cancer using specific enzyme-
linked immunoabsorbent assays (ELISA). Survival curves
were estimated using the method of Kaplan and Meier and
the differences in the survival rates were tested by the log-
rank test. For multivariate analysis of prognostic factors, the
Cox proportional hazard model was used. Proinflammatory
cytokines and sTNF-Rs were higher in the whole group of
patients in comparison to healthy volunteers. IL-10 was
elevated mostly in advanced disease. The increased levels of
IL-10 (>10 pg/ml) were associated with significantly poorer
survival of patients, while the levels of the other cytokines
and sTNF-Rs showed no correlation with prognosis. The
increased level of IL-10 is an independent unfavorable
prognostic factor in patients with gastric cancer. 
It is generally assumed that the immune response in
malignant disease is impaired and is thus associated with a
poor prognosis. Clinically detectable dysfunction of the
immune system is generally observed in cases of
disseminated disease. Therefore research studies are focused
on subclinical measurements of cell function, inflammatory
mediators, cytokines and growth factors. There is no
common pattern of the immune dysfunction observed. It
probably depends on the tumour-host reaction, tumour site
and stage of the disease. 
Cytokines have been investigated in numerous studies as
tumour markers, a prognostic tools for staging and survival
and prognostic factors of postoperative complications.
Proinflammatory cytokines were reported to play a role in
cancer cachexia and metastasis promotion while
antiinflammatory cytokines (interleukin (IL)-10, IL-4) have
mainly been described as markers of more advanced disease
(1-3). 
It has been reported that the serum level of the
proinflammatory cytokine IL-18 is elevated in patients with
stage II and III gastric cancer and associated with poor survival
(4). Significant discrepancies have been reported on the serum
levels of proinflammatory cytokines in patients with cancer.
Thus, in gastric cancer tumour necrosis factor (TNF) was
elevated (>10 pg/ml) in 7.7 or 26.0% of patients in two different
studies (5, 6) and it was neither related to the stage of disease
nor prognosis, while in another study elevated levels of TNF
were observed in advanced gastric cancer and were associated
with a poor prognosis (7). On the other hand, low serum levels
of IL-12 have been associated with more advanced stages of
gastric and colorectal carcinomas and tended to be associated
with lymph node metastasis and carcinoembryonic antigen
(CEA) positive tumours greater than 5 cm in diameter, but this
was based on a small group of patients (8). Another small study
has indicated that elevated serum IL-12 was associated with
prolonged survival of patients with metastatic lung and
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gastrointestinal cancer (9). Data concerning the level of anti-
inflammatory cytokine IL-10 in gastric cancer patients display
discrepancies. A study performed on 68 patients showed no
correlation between serum IL-10 level and the clinical course
of disease (10). On the other hand, the serum level of this
cytokine did correlate with the progression of breast cancer (11).
In an experimental model, high intraperitoneal concentrations
of IL-10 prevented peritoneal dissemination of gastric cancer
(12). Preoperative serum levels of IL-10 in patients with colon
cancer have been shown to be useful markers for predicting
both the likelihood of curative surgery being performed and, in
combination with the 16th postoperative day serum levels,
tumour recurrence (13).
These discrepant observations prompted the present
systemic studies on the occurrence and clinical significance
of proinflammatory (TNF, IL-12 and IL-18) and anti-
inflammatory (IL-10) cytokines in the plasma of a large
group of patients with different stages of gastric cancer. 
Patients and Methods
Patients. A total of 136 consecutive patients with biopsy-proven
gastric carcinoma treated at a single institution between 1997 and
2007 were investigated. All the patients underwent radical (n= 92)
or palliative (n=44) gastric resection.
The postsurgical clinicopathological staging system of the
International Union against Cancer (UICC) TNM Classification of
Malignant Tumors (5th edition) was used for classification of the
disease (14). The patient group consisted of 52 women and 84 men,
with a mean age 61.5±11.9 years, range 28 to 83 years. At the time of
final follow-up, 86 out of the 136 patients (63%) had died, and the
median follow-up for the surviving individuals was 82.6 months. Table
I shows the clinicopathological characteristics of the patients. Blood
was taken preoperatively and plasma samples were stored at –80˚C.
The plasma levels of proinflammatory (TNF, IL-12p40, IL-12p70, and
IL-18) and antiinflammatory (IL-10) cytokines were determined. None
of the patients had received chemotherapy or radiotherapy before
surgery and did not show clinical symptoms of inflammatory
disorders. The Ethical Committee of the Jagiellonian University
approved the study. Informed consent was obtained from the patients.
The control group consisted of 42 healthy volunteers (M/F: 25/12, age:
46.5±12.8).
Determination of cytokine levels. Cytokine levels were determined by
specific enzyme-linked immunoabsorbent assay (ELISA) using
commercially available kits: TNF (EASIA Biosource, Nivelles,
Belgium), IL-12p40, IL-12p70 and IL-10 (PharMingen, San Diego,
CA, USA), IL-18 (MBL, Nagoya, Japan), soluble TNF receptor
(sTNF-R) and R-II (R & D Systems, MN, USA). The cut-off levels of
each assay were as follows: TNF: 15.6 pg/ml, IL-10, IL-12p40 and IL-
12p70: 7.8 pg/ml; IL-18: 12.5 pg/ml, sTNF-RI and R-II –7.8 pg/ml.
Statistical analysis. The differences between the levels of cytokines
in the patients groups were analysed using Student’s t-test. All the
quantitative variables were described as medians and their 95%
confidence intervals (95% CI). The Mann–Whitney U-test and the
Chi-square test, were used where appropriate to compare the
distribution of individual variables between groups. Survival data
were analyzed according to the Kaplan-Meier method and included
postoperative mortality. The log-rank test was used to detect
differences between groups in the univariate analysis of potential
prognostic factors. Multivariate analysis was performed using a Cox
proportional hazards model with a backward stepwise selection
procedure. Variables in the Cox proportional hazards model
included: age, degree of differentiation, tumour location, lymph
node status, distant metastases, splenectomy and IL-10 level. Age,
degree of differentiation, tumour localisation, and splenectomy were
withdrawn using a backward stepwise selection procedure. The
probability for entering the model was 0.05 and for removal from
the model 0.100. A significance level (p) <0.05 was considered
statistically significant. Statistical analysis was performed using the
SPSS v.14 (SPSS Inc., Chicago, IL, USA) software package and
GraphPad Prism (San Diego, CA, USA) software.
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Table I. Demographical and clinicopathological characteristics of
patients with gastric cancer. 







































Cytokine levels in plasma of patients with gastric cancer.
TNF was detected in 52% of the patients and, in comparison
to the control group, its level was significantly higher in the
whole patient group and in stage I and IV the disease. There
were no significant differences in the mean levels between
the stages (Figure 1A). IL-12p40 and IL-12p70 were
significantly elevated in all the stages (Figure 1B and 1C).
IL-18 was elevated in the whole group of patients and in
stages II and IV compared to the control (Figure 2A). IL-10
was significantly elevated in the whole group of patients
compared to the control mostly due to an increase observed
in stage IV disease (Figure 2B). Apparently, there was no
clear association of the elevated levels of any of the studied
cytokines with the histopathological type of tumour
according to Lauren’s classification (data not shown).
Subanalysis of the cytokine levels with other prognostic
factors revealed significantly higher levels of TNF and IL-
18 in N patients with N(–) vs. N(+) status, while IL-12p40
was elevated in those with T1/2 vs. T3/4 tumours. There was
no association of IL-10 mean levels with T, N or M status
(Table II). 
The levels of sTNF-RI and R-II were also determined in
60 randomly chosen cancer patients. Both sTNF-Rs were
significantly higher in the total group of patients and in the
patients with stage III and IV disease (Figure 3). The
sTNF-RI and R-II increase was associated with tumour
depth and N status (Table III). Regression analysis revealed
no correlation between the levels of sTNF-Rs and TNF
(data not shown). 
The impact of increased plasma levels of cytokines on
prognosis. Univariate analysis of prognostic factors in this
group of patients revealed that T, N, M status, radicality of
resection, splenectomy and the level of IL-10 had a
significant influence on survival. No such relationship was
observed for the level of proinflammatory cytokines and
sTNF-Rs (data not shown). Multivariate analysis performed
on the set of factors selected via the univariate method
confirmed that a level of IL-10> 10 pg/ml was an
independent prognostic factor (Table IV).
When the clinicopathological variables of the groups of
patients with IL-10 levels above and below the cut-off point
Szaflarska et al: Cytokines in Gastric Cancer
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Figure 1. Preoperative plasma levels of TNF (A), IL-12p40 (B) and IL-
12p70 (C) in patients with gastric cancer. P<0.05 compared to control.
Table II. Pathological parameters of the tumour and cytokine levels.
Tumour TNF IL-12 p40  IL-18 IL-10 
parameter (pg/ml) (pg/ml) (pg/ml) (pg/ml)
(mean±SD) (mean±SD) (mean±SD) (mean±SD) 
pT1, pT2 80.9±152.3 262.7±816.1 232.69±158.69 19.94±83.09
pT3, pT4 52.2±203.2 71.4±88.8* 278.94±233.82 18.30±57.86
N(–) 78.4±149.2 244.7±808.4 203.36±149.08 17.37±81.20
N(+) 53.1±204.9* 79.8±129.4 292.14±231.89* 19.52±59.41
M0 67.6±198.9 142.9±498.7 273.17±219.72 18.26±67.46
M1 12.0±22.0 47.9±58.5 171.80±106.43 25.06±65.48
*Statistically significant at p<0.05, comparison within groups.
were compared, no significant differences were found (Table
V). The cumulative survival of these two groups of patients
(Figure 4) indicated that the 5-year survival of patients with
preoperative elevated levels of IL-10 was significantly
shorter (p<0.002). This was also true when the survival of
patients without distant metastasis (n=122) was analysed
(data not shown). 
Discussion
The present study showed that proinflammatory cytokine
levels increased in the plasma of some gastric cancer
patients. TNF was significantly increased in 52% patients
with gastric cancer in comparison to healthy volunteers, but
no clear association with the stage of disease was observed.
Increased values of TNF were also found in patients with
colorectal cancer (15), hepatocellular carcinoma and
metastatic liver carcinoma (16, 17). On the other hand, TNF
was undetectable in the serum of patients with metastatic
breast carcinoma (18) and patients with gastrointestinal
cancer-associated cachexia (19-21). The present data showed
that TNF was higher in stages I and IV of the disease. These
ANTICANCER RESEARCH 29: 5005-5012 (2009)
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Figure 2. Preoperative plasma levels of IL-18 (A) and IL-10 (B) in
patients with gastric cancer. P<0.05 compared to control.
Table III. Pathological parameters of the tumour according to sTNF-RI




pT1, pT2 63.1±59.6 148.0±75.0





*Statisticaly significant at p<0.05, comparison within groups.
Table IV. Multivariate analysis of prognostic factors for survival (Cox
proportional hazard model). 
Parameter HR (95% CI) P-value
Depth of infiltration (UICC)
T1 1 0.618
T2 2.296 (0.372-14.162) 0.370
T3 2.337 (0.424-12.899) 0.330
T4 3.273 (0.509-21.040) 0.212
Lymph nodes metastasis (UICC)
N0 1 <0.001
N1 3.215 (1.131-9.141) 0.028
N2 5.110 (1.765-14.797) 0.003
N3 9.629 (3.224-28.759) <0.001
Distant metastasis
M0 1
M1 2.000 (0.942-4.247) 0.071
Degree of differentiation
Well 1 0.926
Moderate 1.274 (0.337-4.814) 0.721










observations taken together may suggest that TNF has no
role in cancer-related cachexia in man, at least in some types
of cancer, but may play a significant role in the regulation of
the inflammatory host response to the growing tumour (22)
which is in keeping with our previous observations (21, 23). 
It appears that TNF is produced mainly by peripheral blood
mononuclear cells (PBMCs), but not locally, in the primary
tumour or in the regional lymph nodes of gastric cancer
patients (5). Our previous observations indicated that PBMCs
isolated from gastric cancer patients do not release TNF
spontaneously in vitro, however they do produce TNF, 
IL-12p40 and IL-10 upon stimulation with cancer cells (24).
Under such circumstances monocytes are the main source of
cytokines and the question arises as to whether tumour
infiltrating macrophages (TIM) may be responsible for the
production of these cytokines. Abundant TNF mRNA was
demonstrated in TIM infiltrating colorectal cancer (25).
However, TIM may produce TNF in some, but not other,
types of tumours (26). Elevated serum levels of sTNF-RI and
R-II were observed in ovarian, endometrial and cervical
carcinomas, and correlated with worse clinical outcome (27-
29). Serum levels of sTNF-RI were also elevated in gastric
cancer, especially in patients with stage IV disease with
cachexia (30). However, in other studies, low serum levels of
Szaflarska et al: Cytokines in Gastric Cancer
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Table V. Demographical and clinicopathological characteristics of
patients with gastric cancer according to level of IL-10. 
Parameter Percentage of patients P-value
IL-10< IL-10>
10 pg/ml 10 pg/ml
Gender
Female 37.9 35.9 0.828
Male 62.1 64.1
Age
≤70 years 75.8 61.5 0.096
>70 years 24.2 38.5
Depth of infiltration (UICC)




Lymph nodes metastasis (UICC)





M0 88.4 92.3 0.504
M1 11.6 7.7
Stage




Radicality of resection 
R0 73.4 57.9 0.081
R1/2 26.6 42.1
Tumour histopathology




1 16.0 8.8 0.588
2 17.3 20.6
3 66.7 70.6
Figure 3. Plasma levels of sTNF-RI and R-II in patients with gastric
cancer. P<0.05 compared to control.
sTNF-RII in cervical cancer were detected and seemed to be
a poor prognostic factor (31). In the present investigations,
circulating sTNF-Rs were increased mostly in advanced
gastric cancer (stages III and IV). However, they were not
related to prognosis and showed no reverse correlation with
TNF levels. The meaning of these findings is unclear as TNF
is biologically active when bound to sTNF-Rs (32).
In contrast to other studies, the present results clearly
indicated increased levels of IL-12p40 and bioactive 
IL-12p70 in the plasma of the patients in all stages of gastric
cancer. Elevated IL-18 was observed mainly in stages II and
III, but less in stage IV gastric cancer (22) and in bladder
cancer and interestingly more in Ta than T1-T4 and in G1
than G2/3 tumours (33). The present findings showed
increased levels of IL-18 in the whole group of patients and
in stages II and IV.
Elevated serum levels of IL-10 in patients with resectable
hepatocellular carcinoma and advanced gastrointestinal
malignances were observed and appeared to be an
independent adverse prognostic factor (34, 35). Elevated
concentrations of IL-10 in the ascitic fluid of gastric cancer
patients also correlated with an unfavorable outcome (36),
but a lack of differences in the production of IL-10 by
PBMCs of gastric cancer patients of different clinical
stages were observed (24, 37). The present study showed
elevated plasma IL-10 in the patients and overall in stage
IV, but no clear association with other clinicopathological
parameters (TNM). 
Observations on the association of serum levels of
different cytokines and prognosis in cancer patients are also
contradictory. As elevated TNF was associated with disease
progression and malnutrition in hepatocellular carcinoma, it
was assumed to be a poor prognostic indicator (17, 19).
However, the present data on gastric cancer do not support
this conclusion as the increased plasma TNF had no
association with survival. Apparently, the same was also true
for IL-12p40, which is not in keeping with the observation
of Lissoni et al. that high IL-12 levels (unspecified form)
were associated with longer survival in patients with
different types of solid tumours (9). As far as IL-18 is
concerned, the present observations differ from the report of
Kawabata et al. (4) showing that preoperatively increased 
IL-18 was a poor prognostic marker in patients with gastric
cancer. In the present study, IL-18 levels were not associated
with prognosis. 
The only association of cytokine level with prognosis in
the present study was the significantly shortened overall
survival of the patients with elevated IL-10. This was in
keeping with observations that serum IL-10 is an adverse
prognostic factor in patients with different types of advanced
solid tumours (34) and in unresectable hepatocellular
carcinoma (35), but in contrast to other recent data showing
no impact on the clinical course of gastric cancer (10). The
present data, based on a large group of gastric cancer patients
indicated that increased plasma IL-10 was associated with
significantly shortened 5-year survival. However, the very
recent report of Ikeguchi et al. (38) shows that a high levels
of serum IL-10 is associated with a worse prognosis in
gastric cancer patients, which is in keeping with present data. 
In summary, proinflammatory cytokines (TNF, IL-12, IL-
18) are increased in the plasma of about half of gastric
cancer patients but show no association with prognosis.
Among the cytokines only immunosuppressive IL-10 has an
influence on prognosis, its elevation is associated with
shortened survival and it is an independent prognostic factor. 
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